Elutia Inc (ELUT) USD0.001

Sell:$0.88Buy:$0.92$0.01 (1.23%)

Prices delayed by at least 15 minutes
Sell:$0.88
Buy:$0.92
Change:$0.01 (1.23%)
Prices delayed by at least 15 minutes
Sell:$0.88
Buy:$0.92
Change:$0.01 (1.23%)
Prices delayed by at least 15 minutes

Company Information

About this company

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.

Key people

C. Randal Mills
President, Chief Executive Officer, Director
Matthew B. Ferguson
Chief Financial Officer
Michelle LeRoux Williams
Chief Scientific Officer
Kevin L. Rakin
Lead Independent Chairman of the Board
Guido J. Neels
Director
David Colpman
Independent Director
Brigid A. Makes
Independent Director
Click to see more

Key facts

  • EPIC
    ELUT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US05479K1060
  • Market cap
    $37.99m
  • Employees
    51
  • Shares in issue
    38.08m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.